Drug intelligence / Profile preview

IL-1β-pretreated mesenchymal stem cells

Development stage
Preclinical
Lead developer
Sun Yat-sen University
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

IL-1β-pretreated mesenchymal stem cells (βMSCs) are a modified cell therapy product where human umbilical cord-derived mesenchymal stem cells are stimulated with the pro-inflammatory cytokine interleukin-1β (IL-1β) prior to administration. This pretreatment enhances the therapeutic efficacy of the MSCs by upregulating the expression of miR-146a, an anti-inflammatory microRNA, which is then selectively packaged into exosomes. These exosomes are transferred to macrophages, promoting their polarization toward an anti-inflammatory M2 phenotype. In preclinical studies, βMSCs have demonstrated superior ability to ameliorate symptoms and increase survival in murine models of sepsis compared to naïve MSCs, suggesting a potential modality for treating severe inflammatory disorders.

Other names
βMSCsIL-1β-pretreated MSCsinterleukin-1β-pretreated mesenchymal stem cellsIL-1β-primed mesenchymal stem cellsIL-1β-pretreated human umbilical cord-derived mesenchymal stem cells

Beyond the preview

Go deeper on IL-1β-pretreated mesenchymal stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-1β-pretreated mesenchymal stem cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call